SLNCF - Silence Therapeutics plc

Other OTC - Other OTC Delayed price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in GBP. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
16,150
17,501
12,415
5,479
244
Cost of revenue
9,063
10,880
7,456
3,762
-
Gross profit
7,087
6,621
4,959
1,717
-
Operating expenses
Research development
34,430
35,605
30,765
20,209
13,336
Selling general and administrative
21,552
19,609
20,008
13,983
9,642
Total operating expenses
55,982
55,214
50,773
37,564
22,978
Operating income or loss
-48,895
-48,593
-45,814
-35,847
-22,734
Interest expense
-44
47
8
323
163
Total other income/expenses net
1,046
1,046
-44
-3,679
-130
Income before tax
-43,545
-47,368
-45,856
-36,041
-22,870
Income tax expense
-7,385
-6,879
-6,446
-3,494
-3,288
Income from continuing operations
-36,160
-40,489
-39,410
-32,547
-19,582
Net income
-36,160
-40,489
-39,410
-32,547
-19,582
Net income available to common shareholders
-36,160
-40,489
-39,410
-32,547
-19,582
Basic EPS
-
-0.42
-0.44
-0.40
-0.26
Diluted EPS
-
-0.42
-0.44
-0.40
-0.26
Basic average shares
-
96,585
88,950
81,776
75,127
Diluted average shares
-
96,585
88,950
81,776
75,127
EBITDA
-
-46,839
-45,421
-35,222
-22,225